Insmed (INSM) Profit After Tax (2010 - 2026)
Insmed (INSM) posted quarterly Profit After Tax of -$1.5 million for Q1 2026, up 99.43% year-over-year from -$730574.3 in Q1 2025, and up 99.55% quarter-over-quarter from -$324.7 million in Q4 2025.
Insmed (INSM) Profit After Tax (2010 - 2026) Analysis & Trends
Insmed's Profit After Tax history runs 17 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 99.43% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$693.6 million (up 31.65% YoY), while the FY2025 annual figure was -$1.3 billion, down 39.08% from the prior year.
- Profit After Tax for Q1 2026 stood at -$1.5 million, up from -$324.7 million in the prior quarter.
- The five-year high for Profit After Tax was $562.0 million in Q4 2023, with the low at -$370.0 million in Q3 2025.
- The 5-year median for Profit After Tax is -$157.8 million (2022), against an average of -$123.1 million.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax tumbled 40517.9% in 2022, then jumped 456.22% in 2023.
- Insmed's Profit After Tax stood at -$157.8 million in 2022, then surged by 456.22% to $562.0 million in 2023, then sank by 142.19% to -$237.1 million in 2024, then slumped by 36.97% to -$324.7 million in 2025, then jumped by 99.55% to -$1.5 million in 2026.
- Business Quant data shows INSM's Profit After Tax at -$1.5 million in Q1 2026, -$324.7 million in Q4 2025, and -$370.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.62 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -324.74 Mn |
| Sep 30, 2025 | -370.02 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | -256.58 Mn |
| Dec 31, 2024 | -237.09 Mn |
| Sep 30, 2024 | -220.52 Mn |
| Jun 30, 2024 | -300.61 Mn |
| Mar 31, 2024 | -157.09 Mn |
| Dec 31, 2023 | 562.01 Mn |
| Sep 30, 2023 | -827,000.00 |
| Jun 30, 2023 | -244.81 Mn |
| Mar 31, 2023 | -159.44 Mn |
| Dec 31, 2022 | -157.77 Mn |
| Sep 30, 2022 | -131.60 Mn |
| Jun 30, 2022 | -699,000.00 |
| Mar 31, 2022 | -94.62 Mn |
| Dec 31, 2021 | -433.79 Mn |
| Sep 30, 2021 | -324,000.00 |